【24h】

Testing times

机译:测试时间

获取原文
获取原文并翻译 | 示例
       

摘要

ONCE PRAISED as a miracle cure for covid-19, an antimalarial drug called hydroxychloroquine has rarely been out of the headlines since the start of the pandemic. It was hoped it might find a new use as a therapy in patients who are unwell with the novel coronavirus. But in recent weeks a scientific picture has emerged of a treatment that does not appear to be helping patients at all, and might even be causing harm. Whether it helps seems clear now: it doesn't. When it comes to the harm, though, it turns out that the scientific literature may be misleading. On June 4th the Lancet, a respected medical journal, retracted a high-profile paper published only a month previously. This had suggested that hydroxychloroquine and its analogue, chloroquine, actually increased the death rate in hospitals when taken by those with covid-19. This led the World Health Organisation to halt its trials of the drug. It also caused considerable concern to patients and to those enrolled on other such trials.
机译:曾经称赞为Covid-19的奇迹治愈,曾经是大流行开始以来的抗疟疾药物很少从头条新闻中出来。希望它可能会发现作为患有新型冠状病毒的患者的治疗方法。但最近几周,一个科学的画面出现了一种似乎根本帮助患者的治疗,甚至可能会造成伤害。它现在有助于似乎很清楚:它没有。然而,当涉及伤害时,事实证明,科学文献可能是误导性的。 6月4日,刺血针,尊敬的医学期刊,撤回了一个高调的纸张,只出版了一个月。这表明羟基氯喹及其类似物,氯喹,实际上在Covid-19的人拍摄时实际上增加了医院的死亡率。这导致了世界卫生组织停止其对药物的试验。它还对患者和参加其他此类试验的人造成了相当大的关注点。

著录项

  • 来源
    《The economist》 |2020年第9198期|61-61|共1页
  • 作者

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 22:14:09

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号